SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (242)11/7/2002 12:45:12 PM
From: keokalani'nui  Read Replies (1) | Respond to of 824
 
My notes say trial originally planned for 74 but was expanded to 202 so there should be more than 54 coming.

Not saying results aren't good, but I was trying to find confirmation in first cohort of statement something like "70% population achieves reduction in tumor burden of 30% with V." From 7/16 oncology day CC.

If tumor burden means paraprotein level, OK.

Wilder


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News